Counseling Persistence in EGFR-Mutated NSCLC Therapy

In this segment, Dr. Alexander Spira and Dr. Edward Kim discuss how to counsel patients who are hesitant to continue adjuvant therapy despite feeling well in early-stage EGFR-mutated non–small cell lung cancer (NSCLC). Dr. Kim emphasizes that this is a common clinical scenario, particularly after patients have recovered from surgery and completed initial treatment. He highlights the importance of clearly explaining the long-term goals of therapy, including reducing the risk of recurrence, even when patients are asymptomatic. The discussion focuses on reinforcing the value of persistence, addressing patient concerns, and building trust through transparent communication. Dr. Kim also notes that framing the treatment as a preventive strategy can help patients better understand its purpose. This segment underscores the importance of ongoing patient engagement and education in supporting adherence and ensuring completion of therapy in EGFR-mutated NSCLC.